TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.78 (−16.53%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Taysha Gene Therapies, Inc. saw revenue fall 32.3% to $5.49M over the twelve months to Jun 30, 2026. Free cash flow was -$132.57M.
Revenue
$5.49M
-32.3% vs. a year earlier
Operating income
-$153.16M
TTM Q2 2026
Free cash flow
-$132.57M
TTM Q2 2026
EPS, diluted
-$0.42
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.45B
- P/E ratio
- –
- Price to sales
- 265.09
- Price to book
- 3.75
- Dividend yield
- –
- Free cash flow yield
- -9.12%
Fundamentals
- Revenue
- $5.49M
- Net income
- -$149.63M
- EPS, diluted
- -$0.42
- Free cash flow
- -$132.57M
- Book value per share
- $1.05
- Diluted shares
- 369M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$5.49M-32.3% YoY
Operating income
-$153.16M
Net income
-$149.63M
EPS, diluted
-$0.42
Free cash flow
-$132.57M
Reported periodTrailing twelve months